Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Non-Current Assets data on file, last reported at $207.2 million in Q1 2026.

• Quarterly Non-Current Assets fell 7.14% year-over-year to $207.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $829.5 million (down 9.43% YoY) and the FY2025 annual result came in at $209.9 million, down 7.84% from the prior year.
• Non-Current Assets slipped to $207.2 million in Q1 2026, from $209.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $250.8 million in Q4 2023 to a low of $24.8 million in Q2 2022.
• A 5-year average of $178.4 million and a median of $209.9 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets fell 27.75% — and 2023, when it jumped 719.88%.
• Tracing CPRX's Non-Current Assets over 5 years: stood at $54.8 million in 2022, then jumped by 357.44% to $250.8 million in 2023, then dropped by 9.16% to $227.8 million in 2024, then fell by 7.84% to $209.9 million in 2025, then fell by 1.3% to $207.2 million in 2026.
• The last three Non-Current Assets figures came in at $207.2 million (Q1 2026), $209.9 million (Q4 2025), and $199.1 million (Q3 2025), per Business Quant data.